Global Leadership in RTK Therapeutics

Transforming science to deliver innovative therapies for patients with severe diseases.

Global Leadership in RTK Therapeutics

Developing novel biologic drugs targeting receptor tyrosine kinases (RTKs) for oncology and immunology.

About Kolltan

We are a privately held clinical-stage company focused on the discovery and development of potential best-in-class drug candidates targeting receptor tyrosine kinases that impact oncology and immunology.

more »

Our Values & Culture

Transforming science to deliver innovative therapies for patients with severe diseases.

more »